In this Issue:
Pathogenesis of myeloproliferative disease by CALR mutations in patients with essential thrombocythaemia and myelofibrosis
Plasma L5 levels and prothrombotic pathways leading to stroke
Recurrent VTE and abnormal uterine bleeding with anticoagulant and hormone therapy
VTE risk in breast cancer
GPIb-IX and PARs in thrombin-induced platelet activation
VTE and subsequent cancer risk
ADAMTS-13 and VWF predict VTE in cancer patients
Apixaban for the treatment of VTE in cancer patients
Novel biomarkers in chronic ITP
Platelet MPs reprogram macrophage gene expression and function
Spleen enlargement is a risk factor for thrombosis in essential thrombocythaemia
Please login below to download this issue (PDF)